Evaxion A/S (NASDAQ:EVAX) Price Target Raised to $11.00 at Lake Street Capital

Evaxion A/S (NASDAQ:EVAX) had its target price upped by Lake Street Capital from $6.00 to $11.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a report on Monday. Wall Street Zen raised shares of Evaxion A/S to a “hold” rating in a report on Friday, June 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.50.

Evaxion A/S Price Performance

NASDAQ:EVAX opened at $7.09 on Monday. The stock has a market cap of $9.93 million, a P/E ratio of -5.37 and a beta of 0.23. Evaxion A/S has a one year low of $1.20 and a one year high of $15.50. The company has a fifty day moving average price of $4.11 and a 200 day moving average price of $2.85. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.42 and a quick ratio of 3.42.

Evaxion A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.26). The firm had revenue of $0.04 million for the quarter. Analysts anticipate that Evaxion A/S will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion A/S

An institutional investor recently bought a new position in Evaxion A/S stock. XTX Topco Ltd acquired a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,281 shares of the company’s stock, valued at approximately $30,000. XTX Topco Ltd owned about 1.16% of Evaxion A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.